New Delhi: ‘Dosage Prevention’ (Booster) for Covid-19 – which will be provided from January 10 to health workers and front lines, and above 60 with comorbidity – will have the same vaccine with the first and second doses, the government said on Wednesday.
“Those who get Covaxin will get Covaxin and those who get the covishield will get a covishield,” said member of the member of Niti Aayog, Dr.
VK Paul said.
On December 27, TOI is the first to report that the third or ‘dose of precautions’ will consist of the same vaccine given as the first and second dose for certain individuals.
Covid cases have increased by more than 6.3 times over the past eight days, with Omicron to become the dominant variant triggering rising in cities, health officials said.
The participation of everyday case has increased 0.79% on 29 to 53% on January 5, a quick increase in Koronavirus infection and a surge in the hospital lately.
But most cases are mild and only a few ventilators or oxygen support are needed.
Chennai is more thanNas per projection of the government, almost 3 health and the forefront of crore workers is expected to qualify in January for a booster or “Covid Vaccine Prevention Action” which will be given with a nine-month pause after the second dose.
In addition, 2.8 crores in the 60-plus age group with comorbidity are projected to qualify throughout the country.
UP, Maharashtra, WB and Tamil Nadu have the highest population in this category.
However, very few people like that can actually be eligible to receive the third dose in January after completing a nine-month gap.
Read Tally Alsodaily Crosses 90,000, Mumbai Logs 15,014 Case Barunew Delhi: The case continues to grow exponentially as a daily calculation that crosses 90,000 marks on Wednesday.
When submitting a story, 90,793 cases have been reported while the numbers of Tripura and Sikkim are still awaited.
In 90,000 cases, Wednesday’s surge compared to the previous government stated that it kept the tab on the information that appeared, science and data about mixing vaccines and heterogal approaches.
While various clinical trials are underway to assess the level of safety and efficacy if the vaccine developed on different platforms is mixed, the government has decided to stick to the same vaccine for booster shot because there is currently no concrete scientific evidence to justify the mixing of vaccines, said one Official.
The National Technical Advisory Group on immunization (NTagi) has also evaluated international data for mixing vaccines.
However, data from several countries has raised concerns about safety because the reactogenicity produced is high in several people after receiving a dose of booster from the vaccine which is different from the first two doses.